Gilead's ($GILD) hep C wonder combo, Harvoni, boasts cure rates as high as 99.1%, and analysts have said they expect it to rack up $10 billion a year in sales, becoming the fastest-growing drug of all time on the way there. But if all of that's the case, then why are U.S. scripts lagging [...]